Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes | Zendy

Florian Blaschke | Zendy; Yasunori Takata | Zendy; Evren Caglayan | Zendy; Ronald E. Law | Zendy; Willa A. Hsueh | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes

Author(s) -

Florian Blaschke,

Yasunori Takata,

Evren Caglayan,

Ronald E. Law,

Willa A. Hsueh

Publication year - 2005

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/01.atv.0000191663.12164.77

Subject(s) - type 2 diabetes , obesity , peroxisome proliferator activated receptor , peroxisome proliferator activated receptor gamma , endocrinology , medicine , receptor , diabetes mellitus , peroxisome proliferator activated receptor alpha , chemistry , nuclear receptor , biochemistry , transcription factor , gene

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear hormone receptor superfamily. The 3 PPAR isotypes, PPAR-alpha, PPAR-gamma, and PPAR-delta, play a key role in the regulation of lipid and glucose metabolism. Obesity and the interrelated disorders of the metabolic syndrome have become a major worldwide health problem. In this review, we summarize the critical role of PPARs in regulating inflammation, lipoprotein metabolism, and glucose homeostasis and their potential implications for the treatment of obesity, diabetes, and atherosclerosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research